Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
This article was originally published in The Pink Sheet Daily
Executive Summary
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.